Wang Peng, Zhang Xiao, Shao Shuo-Han, Wu Fa, Du Fei-Zhou, Zhang Jun-Feng, Zuo Zhi-Way, Jiang Rui
Department of Radiology, The General Hospital of Western Theater Command, Chengdu 610083, Sichuan Province, China.
World J Clin Cases. 2022 Oct 6;10(28):10180-10185. doi: 10.12998/wjcc.v10.i28.10180.
Renal cell carcinoma (RCC) with Xp11.2 translocation/TFE3 gene fusion is a rare and distinct subtype of RCC that is classified under tumors with translocation of the microphthalmia-associated transcriptional factor.
We report an adult case of Xp11.2 translocation advanced RCC with metastasis (T3aN1M1), after targeted treatment, alcohol ablation, and transarterial chemoembolization, who eventually underwent successful surgical excision. No recurrence or transfer was seen within one year, and the survival period was more than 3 years. A review of the relevant literature was conducted to improve our understanding of the pathogenesis, epidemiology, clinical manifestations, diagnosis, differential diagnosis, treatment, and other aspects of the disease.
Transarterial chemoembolization and ablation did not achieve the desired tumor reduction in this patient, but had a significant effect on reducing intraoperative bleeding and inhibiting tumor activity.
伴有Xp11.2易位/TFE3基因融合的肾细胞癌（RCC）是一种罕见且独特的RCC亚型，归类于小眼相关转录因子易位的肿瘤。
我们报告1例成年Xp11.2易位晚期RCC伴转移（T3aN1M1）患者，经靶向治疗、酒精消融和经动脉化疗栓塞后，最终成功接受手术切除。1年内未见复发或转移，生存期超过3年。进行了相关文献复习，以提高我们对该疾病的发病机制、流行病学、临床表现、诊断、鉴别诊断、治疗及其他方面的认识。
经动脉化疗栓塞和消融在该患者中未达到预期的肿瘤缩小效果，但对减少术中出血和抑制肿瘤活性有显著作用。
